Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 1/2013

01.02.2013 | Basic and Applied Science (M Frieri, Section Editor)

Role of Nuclear Factor-ĸB in Breast and Colorectal Cancer

verfasst von: Adeel Zubair, Marianne Frieri

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this review article is to highlight articles and new research regarding the link between NF-ĸB and several cancers. This review presents the most up-to-date NF-ĸB research and how it links this important transcription factor with hematology and oncology. It was written by conducting a thorough search of Pubmed as well as several journals such as Cancer, Nature, Science, Cell and those of one of the authors. The articles relating to the link between NF-ĸB and cancer were used to write this review. The results of this study clarified that there is a critical link between NF-ĸB and cancer. NF-ĸB has often been implicated in a variety of different diseases and it plays a variety of roles in cell survival, differentiation, and proliferation of cells. In cancer, NF-ĸB plays a pivotal role by facilitating oncogenesis as well as metastasis. A thorough understanding of NF-ĸB and its role in cancer can lead to future studies and drug development which could provide a novel option in the treatment of this disease.
Literatur
1.
Pazin MJ, Sheridan PL, Cannon K, et al. NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev. 1996;10:37–49.PubMedCrossRef
2.
Silverman N, Maniatis T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev. 2001;15:2321–42.PubMedCrossRef
3.
Ghosh S, May MJ, Kopp EB. NF-kB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–60.PubMedCrossRef
4.
Shishodia S, Amin HM, Lai R, et al. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol. 2005;70:700–13.PubMedCrossRef
5.
Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell. 2001;7:401–9.PubMedCrossRef
6.
7.
8.
•• Hayden MS, Ghosh S. NF-kB in immunobiology. Cell Res. 2011;21:223–44. This excellent review focused on innate and adaptive immune responses, development and maintenance of cells and tissues, areas of recent progress while also providing a broad overview of the roles of NF-κB in mammalian immunobiology. PubMedCrossRef
9.
Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26:203–34.PubMedCrossRef
10.
• Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem. 2010;336:25–37. The mechanism that leads to constitutive activation of NF-kappaB in hematological, gastrointestinal, genitourinary, gynecological, thoracic head and neck, breast, and skin cancers, and the ways NF-kappaB is activated are the topics of discussion in this review. PubMedCrossRef
11.
Giri DK, Aggarwal BB. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem. 1998;273:14008–14.PubMedCrossRef
12.
Ghosh S, Baltimore D. Activation in vitro of NF-kB by phosphorylation of its inhibitor IkB. Nature. 1990;344:678–82.PubMedCrossRef
13.
Beg AA, Baldwin Jr AS. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev. 1993;11:2064–70.CrossRef
14.
Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene. 2006;25:6706–16.PubMedCrossRef
15.
Mansur A, Karnik A, Frieri M. Nitric oxide production and apoptosis by gp 120. Allergy and Asthma Proc. 2000;21:145–9.CrossRef
16.
Dzhindzhikhashvili M, Jaghab MA, Frieri M. Lymphadenopathy, productive cough, eosinophila and a new onset acquired immundeficiency syndrome. Allergy Asthma Proc. 2011;32:1–6.CrossRef
17.
Mansur A, Therattil J, Frieri M. An atypical case of hypogammaglobulinemia. Ann Allergy Asthma Immunol. 2000;84:583–6.PubMedCrossRef
18.
Frisella PD, Joks R, Frieri M. Transforming growth factor-beta. A Role in the upper airway and rhinosinusitis: D. Pteronyssinusi induced apoptosis with pulmonary alveolar cells. Am J. Rhinology. 2011;25:231–5.CrossRef
19.
Frieri M. Accelerated atherosclerosis in systemic lupus erythematosus. Role of proinflammatory cytokines and therapeutic approaches. Current Allergy & Asthma Report. 2011;12(1):25–32.CrossRef
20.
Frieri M, Samih M, Liu H, et al. Toll-like receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients. J Nephrol. 2012.
21.
Frieri M. Chemotherapy Effects in an Infant with Familial Hemophagocytic Lymphohistiocytosis. Int-J World Allergy Org. 2006; 18/6.
22.
•• Hurtado-Cordovi JM, Avezbakiyev B, Frieri M et al. Inflammatory Malignant Fibrous Histiocytoma Presenting with a Leukemoid Reaction: A Case Report and Review of the Literature. Case Reports in Medicine. Volume 2012. ISRN Oncology, 2012. Following review of medical literature, this appears to be the first reported case of inflammatory cutaneous MFH associated with a leukemoid reaction. This histological variant is rare, and carries a poor prognosis. Therefore there is a need for investigating alternative therapies capable of improving the survival of these patients.
23.
Hinohara K, Gotosh N. Inflammatory signaling pathways in self-renewing breast cancer stem cells. Curr Opin Pharmacol. 2010;10:650–4.PubMedCrossRef
24.
Baker RG, Hayden MS, Ghosh S. NF-kB, inflammation, and metabolic disease. Cell Metab. 2011;12:11–22.CrossRef
25.
Aranha MM, Borralho PM, Ravasco P, et al. NF-κB and apoptosis in colorectal tumourigenesis. Eur J Clin Invest. 2007;37:416–24.PubMedCrossRef
26.
Angileri FF, Aguennouz M, Conti A, et al. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer. 2008;112:2258–66.PubMedCrossRef
27.
Anto RJ, Mukhopadhyay A, Denning K, et al. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis. 2002;23:143–50.PubMedCrossRef
28.
Ahn KS, Sethi G, Aggarwal BB. Simvastatin potentiates TNF-alfa-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalfa kinase and TGF-beta-activated kinase-1. J Immunol. 2007;178:2507–16.PubMed
29.
Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkB activation. J Biol Chem. 1997;272:2042–5.PubMedCrossRef
30.
31.
Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621–63.PubMedCrossRef
32.
Karin M, Greten FR. NF-KappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59.PubMedCrossRef
33.
Kumar A, Takada Y, Boriek AM, et al. Nuclear factor-kappaB: its role in health and disease. J Mol Med. 2004;82:434–48.PubMedCrossRef
34.
35.
Sethi G, Ahn KS, Sandur SK, et al. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J Biol Chem. 2006;281:23425–35.PubMedCrossRef
36.
van der Saag PT, Caldenhoven E, van de Stolpe A. Molecular mechanisms of steroid action: a novel type of crosstalk between glucocorticoids and NF-kappa B transcription factors. Eur Respir J Suppl. 1996;22:146s–53s.PubMed
37.
Noguchi Y, Makino T, Yoshikawa T, et al. The possible role of TNF-alpha and IL-2 in inducing tumor-associated metabolic alterations. Surg Today. 1996;26:36–41.PubMedCrossRef
38.
Marrogi A, Pass HI, Khan M, et al. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res. 2000;60:3696–700.PubMed
39.
Kalgutkar AS, Zhao Z. Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. Curr Drug Targets. 2001;2:79–106.PubMedCrossRef
40.
Ghosh CC, Ramaswami S, Juvekar A, et al. Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IκBα. J Immunol. 2010;185:3685–93.PubMedCrossRef
41.
Antoon JW, White MD, Slaughter EM, et al. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol and Ther. 2011;7:678–89.CrossRef
42.
Bertucci F, Finetti P, Rougemont J, et al. Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy. Cancer Res. 2006;64:8558–65.CrossRef
43.
deGraffenried LA, Chandrasekar B, Friedrichs WE, et al. NF-Kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol. 2004;15:885–90.PubMedCrossRef
44.
Biswas DK, Singh S, Shi Q, et al. Crossroads of estrogen receptor and NF-kappaB signaling. Sci STKE. 2005;288:27.
45.
Evans MJ, Eckert A, Lai K, et al. Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circ Res. 2001;89:823–30.PubMedCrossRef
46.
Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992;10:1014–24.PubMed
47.
Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440:692–6.PubMedCrossRef
48.
Frasor J, Weaver A, Pradhan M, et al. Positive Crosstalk between Estrogen Receptor and NFκB in Breast Cancer. Cancer Res. 2010;69:8918–25.CrossRef
49.
Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab. 2005;16:46–52.PubMedCrossRef
50.
Hinohara K, Kobayashi S, Kanauchi H, et al. ErbB receptor tyrosine kinase/NF-{kappa}B signaling controls mammosphere formation in human breast cancer. PNAS. 2012;109(17):6584–9.PubMedCrossRef
51.
Kuukasjarvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14:2584–9.PubMed
52.
Lerebours F, Vacher S, Andrieu C, et al. NF-kappa B genes have a major role in Inflammatory Breast Cancer. BMC Cancer. 2008;8:41.PubMedCrossRef
53.
Pan Q, Bao LW, Kleer CG, et al. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther. 2003;2:617–22.PubMed
54.
Riggins RB, Zwart A, Nehra R, et al. The nuclear Factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther. 2005;4:33–41.PubMed
55.
•• Santini D, Perrone G, Roato I, et al. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol. 2011;226:780–4. Receptor activator of NFκB ligand (RANKL), represents the key regulators of bone metabolism both in normal and pathological conditions, including bone metastases. To our knowledge, no previous studies investigated and compared RANK expression in primary tumors and in bone metastases. These data highlight the central role of RANK/RANKL/OPG pathway as potential therapeutic target not only in bone metastasis management, but also in the adjuvant setting.PubMedCrossRef
56.
Santini D, Schiavon G, Vincenzi B, et al. Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. PLoS ONE. 2011;6(4)
57.
Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol. 2007;22:1387–98.PubMed
58.
Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000;6:3282–9.PubMed
59.
Van Laere S, Van der Auwera I, Van den Eynden GG, et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat. 2005;93:237–46.PubMedCrossRef
60.
Van Laere SJ, Van der Auwera I, Van den Eynden GG, et al. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res. 2006;12:3249–56.PubMedCrossRef
61.
Whelan J, Ghersa P, van Huijsduijnen RH, et al. An NF kappa B-like factor is essential but not sufficient for cytokine induction of endothelial leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Nucleic Acids Res. 1991;19:2645–53.PubMedCrossRef
62.
Zhou Y, Eppenberger-Castori S, Eppenberger U, et al. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer. 2005;12:37–46.CrossRef
63.
Zhou Y, Eppenberger-Castori S, Marx C, et al. Activation of nuclear factor-kappab (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol. 2004;37:1130–44.CrossRef
64.
Zhou Y, Yau C, Gray JW, et al. Enhanced NFKB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer. 2007;7:59.PubMedCrossRef
65.
Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, et al. PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol. 2006;132:76–84.PubMedCrossRef
66.
Shin Y, Yoon SH, Choe EY, et al. PMA-induced up-regulation of MMP-9 is regulated by a PKCalpha-NF-kappaB cascade in human lung epithelial cells. Exp Mol Med. 2007;39:97–105.PubMed
67.
Matsumoto G, Namekawa J, Muta M, et al. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res. 2005;11:1287–93.PubMed
68.
Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008;1:19–26.CrossRef
69.
Horst D, Budczies J, Brabietz T, et al. Invasion Associated Up-Regulation of Nuclear Factor kB Target Genes in Colorectal Cancer. Cancer. 2009;4946–4958.
70.
Arnold C, Blum H. Colon cancer: molecular pathogenesis and clinical relevance. Dtsch Med Wochneschr. 2005;130:8009–811.
71.
Goa J, Pfeifer D, He LJ, et al. Association of NFKBIA polymorphism with colorectal cancer risk and prognosis in Swedish and Chinese populations. Scand J Gastroenterol. 2007;42:345–50.CrossRef
Metadaten
Titel
Role of Nuclear Factor-ĸB in Breast and Colorectal Cancer
verfasst von
Adeel Zubair
Marianne Frieri
Publikationsdatum
01.02.2013
Verlag
Current Science Inc.
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 1/2013
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-012-0300-5

Weitere Artikel der Ausgabe 1/2013

Current Allergy and Asthma Reports 1/2013 Zur Ausgabe

Anaphylaxis and Drug Allergy (P Lieberman and S Spector, Section Editors)

Progress in Understanding the Epigenetic Basis for Immune Development, Immune Function, and the Rising Incidence of Allergic Disease

BASIC AND APPLIED SCIENCE (M FRIERI, SECTION EDITOR)

Antibody-based Therapeutics for the Treatment of Human B cell Malignancies

ANAPHYLAXIS AND DRUG ALLERGY (P LIEBERMAN AND S SPECTOR, SECTION EDITORS)

Skin Testing For Beta-Lactam Antibiotics: Impact of the Availability of a Major Determinant

Anaphylaxis and Drug Allergy (P Lieberman and S Spector, Section Editors)

Transient Receptor Potentials (TRPs) and Anaphylaxis

IMMUNOLOGIC/DIAGNOSTIC TESTS IN ALLERGY (JL SCHMITZ, SECTION EDITOR)

Overview of Component Resolved Diagnostics

IMMUNOLOGIC/DIAGNOSTIC TESTS IN ALLERGY (JL SCHMITZ, SECTION EDITOR)

Personalised Medicine and Asthma Diagnostics/Management

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise